Pozelimab

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Geographic Atrophy (GA)

Conditions

Geographic Atrophy (GA)

Trial Timeline

Jan 19, 2026 → Jul 3, 2028

NCT ID

NCT07230834

About Pozelimab

Pozelimab is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Geographic Atrophy (GA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07230834. Target conditions include Geographic Atrophy (GA).

What happened to similar drugs?

1 of 12 similar drugs in Geographic Atrophy (GA) were approved

Approved (1) Terminated (3) Active (8)

✅avacincaptad pegolAstellas PharmaApproved

🔄avacincaptad pegolAstellas PharmaPhase 3

🔄Avacincaptad Pegol + ShamAstellas PharmaPhase 3

❌LampalizumabRochePhase 3

🔄Tinlarebant + PlaceboBelite BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05232110	Pre-clinical	Completed	—	—	CD55-deficient Protein-losing Enteropathy
NCT06003881	Pre-clinical	Completed	—	—	CD55-Deficient Protein-Losing Enteropathy
NCT07142343	Approved	Recruiting	Mar 6, 2026	Jan 31, 2030	CHAPLE Disease
NCT07230834	Phase 1	Recruiting	Jan 19, 2026	Jul 3, 2028	Geographic Atrophy (GA)
NCT04491838	Phase 1	Completed	Aug 3, 2020	Mar 5, 2021	Healthy Volunteer
NCT04209634	Phase 2/3	Completed	Jan 27, 2020	May 2, 2024	CD55-deficient Protein-losing Enteropathy

Competing Products

20 competing products in Geographic Atrophy (GA)

See all competitors

Product	Company	Stage	Hype Score
avacincaptad pegol	Astellas Pharma	Phase 3	40
Avacincaptad Pegol	Astellas Pharma	Phase 2/3	38
avacincaptad pegol	Astellas Pharma	Approved	50
Avacincaptad pegol (ACP)	Astellas Pharma	Pre-clinical	33
Avacincaptad Pegol + Sham	Astellas Pharma	Phase 3	40
ABBV-6628 + SYFOVRE	AbbVie	Phase 1/2	39
FWY003 + Placebo	Novartis	Phase 2	42
CLG561 + LFG316 + Sham injection	Novartis	Phase 2	35
LFG316 + Sham + LFG316 Lower dose	Novartis	Phase 2	35
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
RO7669330 + Syfovre™ + Izervay™	Roche	Phase 1	36
RO7303359	Roche	Phase 1	29
SAR446597 + Sham Comparator	Sanofi	Phase 1/2	39
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)	Ionis Pharmaceuticals	Phase 2	24
Tinlarebant + Placebo	Belite Bio	Phase 3	41
Pegcetacoplan	Apellis Pharmaceuticals	Pre-clinical	24
APL-2 + APL-2	Apellis Pharmaceuticals	Phase 3	34
APL-2, Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	34